COMPASS Pathways Stock (NASDAQ:CMPS)

Forecast Ownership Financials Chart Transcripts

Previous Close

$12.19

52W Range

$4.88 - $15.87

50D Avg

$12.91

200D Avg

$10.40

Market Cap

$1.60B

Avg Vol (3M)

$2.65M

Beta

2.56

Div Yield

CMPS Company Profile

COMPASS Pathways plc is a mental healthcare company with a primary presence in the United Kingdom and the United States. Established in 2020 and headquartered in London, UK, the firm focuses on developing novel treatments. Its key product is COMP360, an investigational psilocybin therapy. This therapy has advanced through Phase IIb clinical trials for treatment-resistant depression and is currently undergoing Phase II trials for post-traumatic stress disorder. The company previously operated under the name COMPASS Rx Limited before rebranding to COMPASS Pathways plc in August 2020.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Yes

Country

Employees

156

IPO Date

Sep 18, 2020

Website

CMPS Performance

CMPS Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	-	-	-
Operating Income	$-179.04M	$-178.21M	$-136.92M
Net Income	$-287.86M	$-155.12M	$-118.46M
EBITDA	$-179.04M	$-148.82M	$-115.24M
Basic EPS	$-3.08	$-2.30	$-2.32
Diluted EPS	$-3.08	$-2.30	$-2.32

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts

Q2 26Aug 05, 26 | 8:00 AM

Q1 26May 13, 26 | 8:00 AM

Q3 25Nov 04, 25 | 8:00 AM

Peer Comparison

Ticker	Company
HRMY	Harmony Biosciences Holdings, Inc.
MPLT	MapLight Therapeutics, Inc.
GHRS	GH Research PLC
DNLI	Denali Therapeutics Inc.
RAPP	Rapport Therapeutics, Inc. Common Stock
LBRX	LB Pharmaceuticals Inc Common Stock
ACAD	Acadia Pharmaceuticals Inc.
PRAX	Praxis Precision Medicines, Inc.
NERV	Minerva Neurosciences, Inc.
DFTX	Definium Therapeutics, Inc.